Advertisement

Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis

      Highlights

      • > 50% of the patients with r/mCC did not go onto another line of therapy following 1L
      • Additional novel therapies are needed in subsequent treatment to address the significant unmet needs of patients with r/mCC
      • The key to maximizing treatment outcomes will be generating more clinical data informing optimized sequencing

      Abstract

      Objective

      Understanding real-world treatment patterns and proportions of eligible patients in each line of treatment is imperative to inform future clinical trial designs and multi-line treatment algorithm development.

      Methods

      We conducted a retrospective observational cohort study of adult women who received first-line (1 L) therapy for r/mCC between 01 September 2014 and 31 December 2019, using The US Oncology Network electronic health records and chart review data. Patients were followed to 31 December 2020. Patient demographic and clinical characteristics, treatment patterns, and clinical outcomes were assessed descriptively.

      Results

      A total of 262 patients with r/mCC met study inclusion criteria (mean age = 53 years). The majority of patients in 1 L received platinum-based chemotherapy doublet plus bevacizumab (66%) or chemotherapy doublet alone (24%). Nearly half the patients (48%) completing 1 L received 2 L therapy. Among these patients, there was no consistent 2 L treatment of choice. Overall median time to treatment discontinuation was 3.5 months from 1 L treatment initiation, and median overall treatment-free interval was 2.1 months from 1 L discontinuation. Besides elevated serum creatinine, abnormal BMI indicated a directional trend for lower likelihood of receiving 2 L. Other predictors may include no prior bevacizumab, worse ECOG, and earlier disease prevention.

      Conclusions

      >50% of the patients who initiated 1 L treatment did not receive 2 L therapy, highlighting the need for novel and effective treatment options. As the treatment landscape continues to evolve, we anticipate that more patients will live longer with more treatment options across multiple lines of therapies in the r/mCC setting.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • Jemal A.
        Cancer statistics, 2022.
        CA Cancer J. Clin. 2022; 72: 7-33https://doi.org/10.3322/caac.21708
      1. Cancer Stat Facts: Cervical Cancer.
        • Elit L.
        • Fyles A.W.
        • Devries M.C.
        • Oliver T.K.
        • Fung-Kee-Fung M.
        Follow-up for women after treatment for cervical cancer: a systematic review.
        Gynecol. Oncol. 2009; 114: 528-535https://doi.org/10.1016/j.ygyno.2009.06.001
        • Alberts D.S.
        • Blessing J.A.
        • Landrum L.M.
        • et al.
        Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study.
        Gynecol. Oncol. 2012; 127: 451-455https://doi.org/10.1016/j.ygyno.2012.09.008
        • Boussios S.
        • Seraj E.
        • Zarkavelis G.
        • et al.
        Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review.
        Crit. Rev. Oncol. Hematol. 2016; 108: 164-174https://doi.org/10.1016/j.critrevonc.2016.11.006
        • Garcia A.A.
        • Blessing J.A.
        • Vaccarello L.
        • Roman L.D.
        Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a gynecologic oncology group study.
        Am. J. Clin. Oncol. 2007; 30: 428-431https://doi.org/10.1097/COC.0b013e31803377c8
        • Leath 3rd, C.A.
        • Straughn Jr., J.M.
        Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials.
        Gynecol. Oncol. 2013; 129: 251-257https://doi.org/10.1016/j.ygyno.2012.12.035
        • Look K.Y.
        • Blessing J.A.
        • Gallup D.G.
        • Lentz S.S.
        A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
        Am. J. Clin. Oncol. 1996; 19: 439-441https://doi.org/10.1097/00000421-199610000-00002
        • Schilder R.J.
        • Blessing J.
        • Cohn D.E.
        Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group.
        Gynecol. Oncol. 2005; 96: 103-107https://doi.org/10.1016/j.ygyno.2004.09.027
        • NCCN
        Clinical Practice Guidelines in Oncology. Cervical Cancer. Version 1.2022.
        (Accessed December 13, 2021)
        • Colombo N.
        • Dubot C.
        • Lorusso D.
        • et al.
        Pembrolizumab for persistent, recurrent, or metastatic cervical Cancer.
        N. Engl. J. Med. 2021; 385: 1856-1867https://doi.org/10.1056/NEJMoa2112435
        • Tewari K.S.
        • Sill M.W.
        • Long 3rd, H.J.
        • et al.
        Improved survival with bevacizumab in advanced cervical cancer.
        N. Engl. J. Med. 2014; 370: 734-743https://doi.org/10.1056/NEJMoa1309748
        • Coleman R.L.
        • Lorusso D.
        • Gennigens C.
        • et al.
        Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
        Lancet Oncol. 2021; 22: 609-619https://doi.org/10.1016/s1470-2045(21)00056-5
      2. US Food and Drug Administration. FDA Approves Pembrolizumab for Advanced Cervical Cancer with Disease Progression During or After Chemotherapy. June 13; 2021 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-cervical-cancer-disease-progression-during-or-after-chemotherapy. Accessed November, 2021.

        • US Food
        • Drug Administration
        FDA Approves Pembrolizumab Combination for the First-line Treatment of Cervical Cancer.
        (Accessed February 25, 2022)
        • Markham A.
        Tisotumab Vedotin: first approval.
        Drugs. 2021; 81: 2141-2147https://doi.org/10.1007/s40265-021-01633-8
        • Mayadev J.
        • Nunes A.T.
        • Li M.
        • Marcovitz M.
        • Lanasa M.C.
        • Monk B.J.
        CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
        Int. J. Gynecol. Cancer. 2020; 30: 1065-1070https://doi.org/10.1136/ijgc-2019-001135
        • Lorusso D.
        • Colombo N.
        • Coleman R.L.
        • et al.
        ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer.
        J. Clin. Oncol. 2020; 38https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS6096
        • Alholm Z.
        • Monk B.J.
        • Ting J.
        • et al.
        Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
        Gynecol. Oncol. 2021; 161: 422-428https://doi.org/10.1016/j.ygyno.2021.03.002
      3. The US Oncology Network.
        (Accessed March 2, 2022)
        • Tewari K.S.
        • Sill M.W.
        • Penson R.T.
        • et al.
        Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (gynecologic oncology group 240).
        Lancet. 2017; 390: 1654-1663https://doi.org/10.1016/S0140-6736(17)31607-0
        • Kim T.E.
        • Park B.J.
        • Kwack H.S.
        • Kwon J.Y.
        • Kim J.H.
        • Yoon S.C.
        Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.
        J. Obstet. Gynaecol. Res. 2012; 38: 1315-1320https://doi.org/10.1111/j.1447-0756.2012.01871.x
        • Chen H.H.
        • Meng W.Y.
        • Li R.Z.
        • et al.
        Potential prognostic factors in progression-free survival for patients with cervical cancer.
        BMC Cancer. 2021; 21: 531https://doi.org/10.1186/s12885-021-08243-3
        • Kato M.K.
        • Tanase Y.
        • Uno M.
        • Ishikawa M.
        • Kato T.
        Brain metastases from uterine cervical and endometrial Cancer.
        Cancers (Basel). 2021; 13https://doi.org/10.3390/cancers13030519
        • Zhang Y.
        • Guo X.
        • Wang G.
        • et al.
        Real-world study of the incidence, risk factors, and prognostic factors associated with bone metastases in women with uterine cervical cancer using surveillance, epidemiology, and end results (SEER) data analysis.
        Med. Sci. Monitor: Intern. Med. J. Exper. Clin. Res. 2018; 24: 6387-6397https://doi.org/10.12659/msm.912071
        • Endo D.
        • Todo Y.
        • Okamoto K.
        • Minobe S.
        • Kato H.
        • Nishiyama N.
        Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort.
        J. Gynecol. Oncol. 2015; 26: 12-18https://doi.org/10.3802/jgo.2015.26.1.12
        • Rose P.G.
        • Java J.
        • Whitney C.W.
        • et al.
        Nomograms predicting progression-free survival, overall survival, and pelvic recurrence in locally advanced cervical Cancer developed from an analysis of identifiable prognostic factors in patients from NRG oncology/gynecologic oncology group randomized trials of Chemoradiotherapy.
        J. Clin. Oncol. 2015; 33: 2136-2142https://doi.org/10.1200/jco.2014.57.7122
        • Kassambara A.
        • Kosinski M.
        • Biecek P.
        • Fabian S.
        Package 'survminer' (v0.4.9).
        • WPT Skelton
        • Castagno J.
        • Cardenas-Goicoechea J.
        • Daily K.
        • Yeung A.
        • Markham M.J.
        Bevacizumab eligibility in patients with metastatic and recurrent cervical cancer: A retrospective review. Clinical medicine insights.
        Oncology. 2018; 12https://doi.org/10.1177/1179554918779587
        • Pottel H.
        • Vrydags N.
        • Mahieu B.
        • Vandewynckele E.
        • Croes K.
        • Martens F.
        Establishing age/sex related serum creatinine reference intervals from hospital laboratory data based on different statistical methods.
        Clin. Chim. Acta. 2008; 396: 49-55https://doi.org/10.1016/j.cca.2008.06.017
        • McLachlan J.
        • Boussios S.
        • Okines A.
        • et al.
        The impact of systemic therapy beyond first-line treatment for advanced cervical Cancer.
        Clin. Oncol. (R Coll. Radiol). 2017; 29: 153-160https://doi.org/10.1016/j.clon.2016.10.002
        • Moon J.Y.
        • Song I.C.
        • Ko Y.B.
        • Lee H.J.
        The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer.
        Medicine (Baltimore). 2018; 97e0340https://doi.org/10.1097/md.0000000000010340
        • Musa F.B.
        • Brouwer E.
        • Ting J.
        • et al.
        Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer.
        Gynecol. Oncol. 2022 Jan 11; (Epub ahead of print)https://doi.org/10.1016/j.ygyno.2021.12.028
        • Chen X.
        • Chen L.
        • Zhu H.
        • Tao J.
        Risk factors and prognostic predictors for cervical Cancer patients with lung metastasis.
        J. Cancer. 2020; 11: 5880-5889https://doi.org/10.7150/jca.46258
        • Jia J.B.
        • Lall C.
        • Tirkes T.
        • Gulati R.
        • Lamba R.
        • Goodwin S.C.
        Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective.
        Insights Imag. 2015; 6: 479-487https://doi.org/10.1007/s13244-015-0417-x